Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in IntangiblesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet Income
Growth Metrics
Income Statement
Others
Ratios

CureVac (CVAC) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for CureVac (CVAC) over the last 6 years, with Q3 2025 value amounting to -$282911.3.

  • CureVac's Capital Expenditures rose 9217.71% to -$282911.3 in Q3 2025 from the same period last year, while for Sep 2025 it was $26.3 million, marking a year-over-year decrease of 6893.95%. This contributed to the annual value of $15.3 million for FY2024, which is 7282.63% down from last year.
  • Per CureVac's latest filing, its Capital Expenditures stood at -$282911.3 for Q3 2025, which was up 9217.71% from -$825198.5 recorded in Q2 2025.
  • CureVac's Capital Expenditures' 5-year high stood at $104.3 billion during Q4 2021, with a 5-year trough of -$84.0 billion in Q2 2021.
  • Moreover, its 5-year median value for Capital Expenditures was -$3.7 million (2024), whereas its average is -$293.9 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 16980176.09% in 2021, then tumbled by 4466894.3% in 2022.
  • CureVac's Capital Expenditures (Quarter) stood at $104.3 billion in 2021, then tumbled by 99.85% to $158.3 million in 2022, then crashed by 38.48% to $97.4 million in 2023, then plummeted by 71.36% to $27.9 million in 2024, then crashed by 101.01% to -$282911.3 in 2025.
  • Its Capital Expenditures stands at -$282911.3 for Q3 2025, versus -$825198.5 for Q2 2025 and -$509112.1 for Q1 2025.